Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 9/20 | 0.44 |
| ▸ | ST6GAL1 | P15907 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphonic Acid SCHEMBL7177132 | 0.83 | TYMP (0.45) | TYMP | |
| SCHEMBL7726480 | 0.82 | P2RY6 (0.49) | TYMPST6GAL1 | |
| SCHEMBL6366294 | 0.82 | P2RY6 (0.49) | TYMPST6GAL1 | |
| SCHEMBL5505017 | 0.82 | TYMP (0.51) | TYMPST6GAL1L3MBTL1LMNATHRB | |
| SCHEMBL5505015 | 0.82 | TYMP (0.51) | TYMPST6GAL1L3MBTL1LMNATHRB | |
| SCHEMBL1737308 | 0.82 | TYMP (0.54) | TYMPST6GAL1L3MBTL1LMNATHRB | |
| SCHEMBL5505051 | 0.81 | TYMP (0.49) | TYMPST6GAL1L3MBTL1LMNATHRB | |
| SCHEMBL5505049 | 0.81 | TYMP (0.49) | TYMPST6GAL1L3MBTL1LMNATHRB | |
| Isobutyraldehyde SCHEMBL7177145 | 0.80 | TYMP (0.54) | TYMP | |
| SCHEMBL5710025 | 0.80 | TYMP (0.62) | TYMPST6GAL1L3MBTL1LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030036649-A1 | 2' modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-02-20 | — | — | US | claimed |
| EP-0497875-B1 | 2' MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2000-03-22 | — | — | EP | claimed |
| EP-0942000-A2 | 2'Modified oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036649-A1 | 2' modified oligonucleotides | DCLRE1B, POLRMT, POLM | TYMP 10/4885ST6GAL1 1797/4885L3MBTL1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.